| Oxymetazoline | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
| Oxymetazoline | hsa00053 | Ascorbate and aldarate metabolism | 4.93E-02 | 1 | P14550 | AKR1A1 | More | |
| Oxymetazoline | hsa00565 | Ether lipid metabolism | 4.93E-02 | 1 | Q8N661 | TMEM86B | More | |
| Oxymetazoline | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
| Oxymetazoline | hsa00830 | Retinol metabolism | 4.25E-02 | 1 | P00325 | ADH1B | More | |
| Oxymetazoline | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
| Oxymetazoline | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
| Oxymetazoline | hsa02010 | ABC transporters | 4.93E-02 | 1 | Q8IZY2 | ABCA7 | More | |
| Oxymetazoline | hsa03013 | RNA transport | 3.98E-02 | 9 | P52298, O14893, P61326, Q7Z3B4, P35658, Q14152, O75822, P78345, Q9Y6A5 | NCBP2, GEMIN2, MAGOH, NUP54, NUP214, EIF3A, EIF3J, RPP38, TACC3 | More | |
| Oxymetazoline | hsa03015 | mRNA surveillance pathway | 1.83E-02 | 3 | Q13362, Q14738, Q9UBU9 | PPP2R5C, PPP2R5D, NXF1 | More | |
| Oxymetazoline | hsa04071 | Sphingolipid signaling pathway | 8.10E-04 | 7 | P21453, Q9H228, P01375, Q13362, Q9BX95, Q16539, P10415 | S1PR1, EDG8, TNF, PPP2R5C, SGPP1, MAPK14, BCL2 | More | |
| Oxymetazoline | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
| Oxymetazoline | hsa04114 | Oocyte meiosis | 3.65E-02 | 3 | P0DP23, Q13362, Q14738 | CALM1, PPP2R5C, PPP2R5D | More | |
| Oxymetazoline | hsa04120 | Ubiquitin mediated proteolysis | 3.44E-02 | 4 | Q14145, Q13042, P62837, Q15751 | KEAP1, CDC16, UBE2D2, HERC1 | More | |
| Oxymetazoline | hsa04146 | Peroxisome | 2.42E-02 | 5 | O43933, P56589, Q9UKG9, O75521, P33121 | PEX1, PEX3, CROT, ECI2, ACSL1 | More | |
| Oxymetazoline | hsa04152 | AMPK signaling pathway | 1.83E-02 | 3 | Q96RR4, Q13362, Q14738 | CAMKK2, PPP2R5C, PPP2R5D | More | |
| Oxymetazoline | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | |
| Oxymetazoline | hsa04261 | Adrenergic signaling in cardiomyocytes | 3.75E-03 | 6 | P07550, P22694, P18848, Q13362, Q14738, P0DP23 | ADRB2, PRKACB, ATF4, PPP2R5C, PPP2R5D, CALM1 | More | |
| Oxymetazoline | hsa04610 | Complement and coagulation cascades | 2.33E-03 | 1 | P0C0L4 | C4A | More | |
| Oxymetazoline | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
| Oxymetazoline | hsa04613 | Neutrophil extracellular trap formation | 7.32E-03 | 13 | O60603, P05164, P08246, Q9UM07, Q6FI13, Q15080, P20160, P08311, O75015, P21730, P21462, O43315, Q16539 | TLR2, MPO, ELA2, PADI4, H2AC18; H2AC19, NCF4, AZU1, CTSG, FCGR3B, C5AR1, FPR1, AQP9, MAPK14 | More | |
| Oxymetazoline | hsa04650 | Natural killer cell mediated cytotoxicity | 5.05E-04 | 7 | P01375, P20963, Q13241, P26718, P26717, Q14953, P26715 | TNF, CD247, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | |
| Oxymetazoline | hsa04657 | IL-17 signaling pathway | 4.27E-03 | 7 | O00463, Q16539, P19875, P14780, Q9UJX4, P80188, P01375 | TRAF5, MAPK14, CXCL2, MMP9, ANAPC5, LCN2, TNF | More | |
| Oxymetazoline | hsa04668 | TNF signaling pathway | 3.55E-02 | 4 | P01375, P18848, P19875, P14780 | TNF, ATF4, CXCL2, MMP9 | More | |
| Oxymetazoline | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
| Oxymetazoline | hsa04728 | Dopaminergic synapse | 2.66E-02 | 3 | Q13362, Q14738, P0DP23 | PPP2R5C, PPP2R5D, CALM1 | More | |
| Oxymetazoline | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | |
| Oxymetazoline | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | |
| Oxymetazoline | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
| Oxymetazoline | hsa04921 | Oxytocin signaling pathway | 3.13E-02 | 3 | P0DP23, Q96RR4, Q13469 | CALM1, CAMKK2, NFATC2 | More | |
| Oxymetazoline | hsa04924 | Renin secretion | 4.04E-02 | 2 | P22694, P07550 | PRKACB, ADRB2 | More | |
| Oxymetazoline | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | |
| Oxymetazoline | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | |
| Oxymetazoline | hsa04932 | Non-alcoholic fatty liver disease | 2.74E-02 | 3 | P01375, P49841, P48023 | TNF, GSK3B, FASLG | More | |
| Oxymetazoline | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Oxymetazoline | hsa04964 | Proximal tubule bicarbonate reclamation | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Oxymetazoline | hsa04966 | Collecting duct acid secretion | 4.93E-02 | 1 | P00918 | CA2 | More | |
| Oxymetazoline | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
| Oxymetazoline | hsa04979 | Cholesterol metabolism | 1.61E-02 | 2 | P38571, P61916 | LIPA, NPC2 | More | |
| Oxymetazoline | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
| Oxymetazoline | hsa05133 | Pertussis | 4.20E-02 | 1 | P0C0L4 | C4A | More | |
| Oxymetazoline | hsa05143 | African trypanosomiasis | 7.50E-04 | 4 | P01375, P69905, P68871, P48023 | TNF, HBA2, HBB, FASLG | More | |
| Oxymetazoline | hsa05144 | Malaria | 1.44E-03 | 5 | P69905, P68871, P01375, P35443, P26718 | HBA2, HBB, TNF, THBS4, KLRK1 | More | |
| Oxymetazoline | hsa05146 | Amoebiasis | 2.41E-02 | 4 | P19875, P01375, P30679, P22694 | CXCL2, TNF, GNA15, PRKACB | More | |
| Oxymetazoline | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
| Oxymetazoline | hsa05167 | Kaposi sarcoma-associated herpesvirus infection | 4.82E-02 | 3 | P23458, Q13469, P0DP23 | JAK1, NFATC2, CALM1 | More | |
| Oxymetazoline | hsa05202 | Transcriptional misregulation in cancer | 1.45E-02 | 12 | Q15532, P41732, P14780, P27930, P14923, Q16548, Q13077, O15550, P35226, P05164, P08246, P24522 | SS18, TSPAN7, MMP9, IL1R2, JUP, BCL2A1, TRAF1, UTX, BMI1, MPO, ELA2, GADD45A | More | |
| Oxymetazoline | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | |
| Oxymetazoline | hsa05212 | Pancreatic cancer | 4.16E-02 | 2 | Q15311, P23458 | RALBP1, JAK1 | More | |
| Oxymetazoline | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
| Oxymetazoline | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Oxymetazoline | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | |
| Oxymetazoline | hsa05412 | Arrhythmogenic right ventricular cardiomyopathy | 4.93E-02 | 1 | P54284 | CACNB3 | More | |
